U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07589595) titled 'A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)' on May 11.
Brief Summary: The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Cognitive Dysfunction
Lewy Body Disease
Synucleinopathies
Amyloid
Intervention:
DRUG: Donanemab
Donanemab administered IV
DRUG:...